These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 24373762

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
    Rutenberg MS, Meister M, Amin PP, Hussain A, Naslund MJ, Kwok Y.
    Brachytherapy; 2016 Oct 01; 15(6):722-729. PubMed ID: 27693225
    [Abstract] [Full Text] [Related]

  • 7. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P, van der Horst C, Kimmig B, Zinsser F, Poppe B, Luetzen U, Juenemann KP, Dunst J, Siebert FA.
    Brachytherapy; 2017 Oct 01; 16(1):186-192. PubMed ID: 28341011
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 10. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I, González-San Segundo C, Vegas JO, Gutierrez C, Hervas A, Cabeza Rodriguez MÁ, Valero Albarrán J, Rodríguez Villalba S, Álvarez Gonzalez A, Sancho Pardo G, Zapatero A, Álvaro PC.
    Radiother Oncol; 2019 Dec 01; 141():156-163. PubMed ID: 31570236
    [Abstract] [Full Text] [Related]

  • 11. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC, Baumann JC, Christodouleas JP, Soffen E.
    Brachytherapy; 2017 Dec 01; 16(2):291-298. PubMed ID: 28139422
    [Abstract] [Full Text] [Related]

  • 12. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA, McBride S, Taggar A, Anderson E, Lin M, Pei X, Weiji S, Voros L, Cohen G, Yamada Y, Zelefsky MJ.
    Brachytherapy; 2017 Dec 01; 16(6):1091-1098. PubMed ID: 28838648
    [Abstract] [Full Text] [Related]

  • 13. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
    Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H.
    Int J Radiat Oncol Biol Phys; 2019 Feb 01; 103(2):335-343. PubMed ID: 30312717
    [Abstract] [Full Text] [Related]

  • 14. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
    Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M, Hsu IC.
    Int J Radiat Oncol Biol Phys; 2007 Mar 15; 67(4):1106-12. PubMed ID: 17197119
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.
    J Urol; 2004 Mar 15; 171(3):1098-104. PubMed ID: 14767279
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
    Chitmanee P, Tsang Y, Tharmalingam H, Hamada M, Alonzi R, Ostler P, Hughes R, Lowe G, Hoskin P.
    Clin Oncol (R Coll Radiol); 2020 Apr 15; 32(4):259-265. PubMed ID: 31708350
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.